Third party manufacturing expected to be brisk.

To boost the bio-equivalent test the KFDA provided special incentives to the pharmaceutical company with an exemption of the bio-equivalent test requirements when the company produces the duplicate product for a third party with their original ingredients and formulas that were already proved of their bio-equivalent tests.

The KFDA confirmed 89 items, most of new drug duplicates including Ac...